Guardant Health, INC Form 4 insider transactions

Guardant Health's Chief Information Officer, Kumud Kalia, reported the vesting of restricted stock units and the subsequent sale of shares to cover tax obligations.

Guardant Health's Chief Commercial Officer, Chris Freeman, reported multiple equity transactions related to RSU and PBRSU vesting on January 1, 2026, including shares withheld for tax obligations.

Guardant Health's Chief Medical Officer, Craig Eagle, reported multiple equity transactions including RSU vestings and shares withheld for tax obligations.

Guardant Health's Chief Technology Officer, Darya Chudova, reported the vesting of various restricted stock units and performance-based restricted stock units on January 1, 2026, alongside shares withheld for tax obligations.

Guardant Health's CFO, Michael Brian Bell, reported multiple stock unit vestings and a tax-related share disposition on January 1, 2026.

Guardant Health Co-Chief Executive Officer AmirAli Talasaz reported the conversion of restricted stock units into common stock and subsequent tax-related dispositions.

Guardant Health's Co-CEO, Helmy Eltoukhy, increased his direct beneficial ownership of common stock by 13,209 shares through restricted stock unit vestings and associated tax withholdings.

Guardant Health Director Steve E. Krognes reported the vesting and acquisition of 154 shares of common stock from restricted stock units.

Guardant Health Director Roberto Mignone converted 264 restricted stock units into common stock, increasing his direct beneficial ownership.

Guardant Health Director Manuel Hidalgo Medina acquired 232 shares of common stock on December 17, 2025, through the vesting of restricted stock units.

Guardant Health Director Tariq Musa sold 116 shares of common stock for $101.46 per share under a pre-arranged Rule 10b5-1 plan.

Guardant Health Director Musa Tariq acquired 250 shares of common stock through the exercise of restricted stock units on December 15, 2025.

Guardant Health's Chief Legal Officer, John G. Saia, reported the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Guardant Health's Chief Information Officer, Kumud Kalia, reported the vesting of restricted stock units and a subsequent tax-related sale of company stock.

Guardant Health's Chief Commercial Officer, Chris Freeman, reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

Guardant Health Co-Chief Executive Officer Helmy Eltoukhy reported the sale of 90,565 shares of common stock for approximately $9.4 million.

Guardant Health's Chief Medical Officer, Craig Eagle, reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

Guardant Health's Chief Technology Officer, Darya Chudova, reported the pre-planned sale of 5,451 shares of common stock for approximately $104.04 per share.

Guardant Health's CFO, Michael Brian Bell, reported the vesting of restricted stock units and subsequent tax withholding on December 15, 2025, under a pre-arranged plan.

Guardant Health Co-CEO AmirAli Talasaz reported sales of 100,000 common shares and transfers to trusts under a 10b5-1 plan.

Guardant Health's Chief Information Officer, Kumud Kalia, sold 2,000 shares of common stock for approximately $104.60 per share under a Rule 10b5-1 plan.

Guardant Health Director Manuel Hidalgo Medina exercised stock options and subsequently sold a portion of the acquired common stock.

Guardant Health's Chief Technology Officer, Darya Chudova, reported the sale of over 22,000 shares of common stock and a transfer of shares to a family trust.

Guardant Health's Chief Commercial Officer, Chris Freeman, sold 31,252 shares of common stock for over $3.2 million on December 5, 2025, under a pre-arranged trading plan.

Guardant Health's Chief Financial Officer, Michael Brian Bell, exercised stock options and subsequently sold a significant number of common shares.

Guardant Health Director Ian T. Clark exercised stock options and subsequently sold a portion of his indirectly held common stock on December 5, 2025, under a Rule 10b5-1 plan.

Guardant Health's Chief People Officer, Terilyn J. Monroe, exercised stock options and subsequently sold a portion of the acquired shares under a pre-arranged 10b5-1 plan.

Guardant Health Director Steve Krognes converted 155 Restricted Stock Units into common stock on November 30, 2025, increasing his direct common stock holdings.

Guardant Health Director Roberto Mignone acquired 264 shares of common stock through the vesting of restricted stock units.

Guardant Health Director Tariq Musa sold 116 shares of common stock for $96.25 per share under a pre-arranged Rule 10b5-1 plan.